Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial - Summary - MDSpire

Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial

  • By

  • Julio Rosenstock

  • Ildiko Lingvay

  • Donna Ryan

  • Ania M. Jastreboff

  • Robert Kushner

  • Andres Acosta

  • Thomas C. Blevins

  • Melissa Choi

  • Faith L. Holmes

  • Timothy Smith

  • Lisa Connery

  • Yao Li

  • Mike Ke Liu

  • Aline Barth

  • Jamie Butcher

  • Antonio Civitarese

  • Huibin Yue

  • Blai Coll

  • June 5, 2026

  • 0 min

Share

Objective:

To evaluate the efficacy, safety, and tolerability of once-daily oral aleniglipron in adults with obesity or overweight and one or more weight-related comorbidity.

Key Findings:
  • All doses of aleniglipron showed a statistically significant reduction in body weight compared to placebo.
  • The least squares mean change in body weight at week 36 was -9.0% for 45 mg, -10.7% for 90 mg, and -12.1% for 120 mg aleniglipron.
  • 86% of participants on 120 mg aleniglipron achieved ≥5% weight loss, compared to 23% in the placebo group.
  • Common treatment-emergent adverse events were gastrointestinal-related, including nausea and diarrhea.
Interpretation:

Limitations:
  • The study duration was limited to 36 weeks, and long-term effects remain to be evaluated.
  • The sample size may limit the generalizability of the findings.
Conclusion:

Original Source(s)

Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial

  • by Julio Rosenstock, Ildiko Lingvay, Donna Ryan, Ania M. Jastreboff, Robert Kushner, Andres Acosta, Thomas C. Blevins, Melissa Choi, Faith L. Holmes, Timothy Smith, Lisa Connery, Yao Li, Mike Ke Liu, Aline Barth, Jamie Butcher, Antonio Civitarese, Huibin Yue, Blai Coll

  • June 5, 2026

Related Content

Can Uric Acid Distinguish Lipedema From Overweight?

Metabolomics analysis identified higher uric acid levels in patients with lipedema and lymphedema, although associations weakened following adjustment for renal insufficiency.

Nonlinear association between serum insulin, visceral fat area, and kidney function in female with type 2 diabetes: a retrospective study

Affordable GLP-1? When Digital Platforms Meet Policy Reform